Merck and SpringWorks Secure Conditional EU Approval for EZMEKLY®, the First Therapy for NF1-Associated Plexiform Neurofibromas in Both Adults and Children Merck, a global leader in science and technology, announced that the European Commission (EC) has granted conditional marketing authorization…
Thermo Fisher and Sanofi Expand Strategic Partnership with U.S. Sterile Manufacturing Deal Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in scientific services, has announced a significant expansion of its strategic collaboration with French biopharmaceutical giant Sanofi. This move…
KalVista Pharmaceuticals Secures UK MHRA Approval for EKTERLY® (sebetralstat), Paving the Way for First Oral On-Demand Treatment for Hereditary Angioedema in the Region KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical-stage pharmaceutical company focused on developing innovative oral therapies for rare…
Samsung Bioepis Unveils European Policy Whitepaper to Bridge Gaps Hindering Biosimilar Access and Market Sustainability Samsung Bioepis Co., Ltd. has published a comprehensive whitepaper titled “Solving the Biosimilar Void in Europe,” aiming to drive reform in biosimilar policy frameworks across…
ViiV Healthcare Broadens Voluntary Licensing Deal with MPP to Include Long-Acting Injectable HIV Treatment in Global Access Push GSK plc (LSE/NYSE: GSK) announced that its majority-owned subsidiary, ViiV Healthcare—a global leader in HIV treatment and prevention, with Pfizer and Shionogi…
WHO-WIPO-WTO Webinar Highlights Role of Public Procurement in Advancing Global Health Equity and Innovation On July 3, 2025, the World Health Organization (WHO), the World Intellectual Property Organization (WIPO), and the World Trade Organization (WTO) jointly hosted a technical webinar…
Jazz Pharmaceuticals Appoints Renee Gala as Chief Executive Officer, Marking a New Chapter in Company’s Growth Strategy Pharmaceuticals today announced a significant leadership transition that marks a pivotal moment in the company’s evolution. The Board of Directors has unanimously appointed…
European Commission Approves TEVIMBRA® (Tislelizumab) with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma BeOne Medicines Ltd., a global biotechnology company dedicated to oncology innovation, today announced that the European Commission (EC) has granted marketing authorization for TEVIMBRA®…
AbbVie and IGI Therapeutics Sign Exclusive Global Licensing Agreement for Trispecific Antibody ISB 2001 AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive global licensing agreement for ISB 2001, IGI’s…
BeOne, a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC) not suitable for curative surgery…
FDA Accepts sNDA for INQOVI® Plus Venetoclax for Newly Diagnosed AML Patients Ineligible for Intensive ChemotherapyCombination therapy met primary efficacy endpoint with no new safety signals; would represent the first all-oral regimen for this patient population if approved Taiho Pharmaceutical…
Trump Floats 200% Tariffs on Pharma Imports, Offers Industry One-Year Grace Period In a move that could significantly reshape the pharmaceutical supply chain and global drug trade, President Donald Trump announced Tuesday that imported pharmaceutical products could face tariffs of…